Anteris Technologies Global/$AVR
1D1W1MYTD1Y5YMAX
Capital at risk
About Anteris Technologies Global
Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.
- Ticker
- $AVR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 174
- Headquarters
- Toowong, Australia
- Website
- anteristech.com
AVR Metrics
BasicAdvanced
$840M
-
-$1.62
-
-
Price and volume
Market cap
$840M
52-week high
$11.06
52-week low
$3.30
Average daily volume
801K
Financial strength
Current ratio
14.197
Quick ratio
14.02
Long term debt to equity
0.912
Total debt to equity
1.32
Interest coverage (TTM)
-580.51%
Profitability
EBITDA (TTM)
-104.496
Gross margin (TTM)
74.98%
Net profit margin (TTM)
-4,619.27%
Operating margin (TTM)
-4,738.36%
Effective tax rate (TTM)
-0.48%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-42.51%
Return on equity (TTM)
-74.65%
Valuation
Price to revenue (TTM)
246.068
Price to book
3.34
Price to tangible book (TTM)
3.34
Price to free cash flow (TTM)
-6.251
Free cash flow yield (TTM)
-16.00%
Free cash flow per share (TTM)
-1.379
Growth
Revenue change (TTM)
-9.56%
Earnings per share change (TTM)
-44.00%
3-year revenue growth (CAGR)
-9.18%
3-year earnings per share growth (CAGR)
-13.35%
Bulls say / Bears say
The company completed aggregate capital raises totaling US$320 million in January 2026, bolstering its cash runway and funding pivotal Phase III PARADIGM Trial and commercial expansion efforts (SEC EX-99.1).
U.S. patient enrollment for the PARADIGM Trial commenced post quarter-end after CMS issued a favorable coverage determination under the TAVR National Coverage Determination 20.32, likely accelerating trial site activation and reimbursement (SEC EX-99.1).
The DurAVR THV utilizes patented ADAPT tissue technology, which is FDA-cleared and has been used clinically in over 55,000 patients, providing a strong safety and regulatory foundation for the DurAVR valve system (SEC EX-99.2).
Net operating cash outflows of US$28.7 million in Q1 2026 underscore a high burn rate tied to clinical and manufacturing activities, raising the risk of future dilutive financings (SEC EX-99.1).
The pivotal PARADIGM Trial’s non-inferiority endpoint in a 1,000-patient head-to-head study against established TAVR devices carries inherent clinical and statistical risks that could delay approval and market entry (SEC EX-99.1).
Forward-looking statements highlight dependency on achieving and maintaining CMS coverage, and unanticipated regulatory or enrollment setbacks could prolong timelines and erode investor confidence (SEC EX-99.2).
Data summarised monthly by Lightyear AI. Last updated on 23 Aug 2026.
Upcoming events
No upcoming events
Funds containing AVR
Fund name | Fund size | $AVR weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.